Joon H. Uhm
#163,333
Most Influential Person Now
Joon H. Uhm's AcademicInfluence.com Rankings
Joon H. Uhmbiology Degrees
Biology
#13068
World Rank
#16593
Historical Rank
Computational Biology
#295
World Rank
#296
Historical Rank
Biochemistry
#2255
World Rank
#2402
Historical Rank
Download Badge
Biology
Joon H. Uhm's Degrees
- PhD Biomedical Sciences University of California, San Francisco
- Bachelors Biochemistry University of California, Berkeley
Why Is Joon H. Uhm Influential?
(Suggest an Edit or Addition)Joon H. Uhm's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Comprehensive genomic characterization defines human glioblastoma genes and core pathways (2009) (1371)
- An Integrated Genomic Analysis of Human Glioblastoma Multiforme (2009) (1167)
- The transcriptional network for mesenchymal transformation of brain tumours (2010) (779)
- IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype (2012) (683)
- Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group (2010) (606)
- Interferon β‐1b decreases the migration of T lymphocytes in vitro: Effects on matrix metalloproteinase‐9 (1996) (357)
- Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme. (2005) (321)
- Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. (2008) (274)
- Medulloblastoma Comprises Four Distinct Molecular Variants (2011) (260)
- Central nervous system tumors. (2007) (203)
- Vitronectin, a glioma-derived extracellular matrix protein, protects tumor cells from apoptotic death. (1999) (174)
- Phase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074. (2011) (160)
- Oligodendrocytes utilize a matrix metalloproteinase, MMP‐9, to extend processes along an astrocyte extracellular matrix (1998) (151)
- Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. (1996) (143)
- The role of integrins in the malignant phenotype of gliomas. (1999) (135)
- Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma (2011) (133)
- Mechanisms of Glioma Invasion: Role of Matrix-Metalloproteinases (1997) (130)
- Phase II Study of Bevacizumab in Combination with Sorafenib in Recurrent Glioblastoma (N0776): A North Central Cancer Treatment Group Trial (2013) (125)
- Aberrant p53, mdm2, and proliferation differ in glioblastomas from long-term compared with typical survivors. (2002) (120)
- Enhanced protein kinase C activity correlates with the growth rate of malignant gliomas in vitro (1991) (120)
- A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K. (2015) (113)
- Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer (2009) (110)
- Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity. (2006) (108)
- Adjuvant Whole-Brain Radiotherapy Versus Observation After Radiosurgery or Surgical Resection of One to Three Cerebral Metastases: Results of the EORTC 22952-26001 Study (2012) (107)
- Cancer-associated IDH1 mutations produce 2-hydroxyglutarate (2010) (107)
- Clonal selection drives genetic divergence of metastatic medulloblastoma (2012) (103)
- Glioblastoma survival in the United States improved after Food and Drug Administration approval of bevacizumab: A population‐based analysis (2013) (96)
- Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: results of North Central Cancer Treatment Group protocol N0177. (2006) (95)
- Glioma invasion in vitro: regulation by matrix metalloprotease-2 and protein kinase C. (1996) (91)
- Presentation, management, and outcome of newly diagnosed glioblastoma in elderly patients. (2013) (90)
- Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme. (2000) (87)
- Combination of Temsirolimus (CCI-779) with Chemoradiation in Newly Diagnosed Glioblastoma Multiforme (GBM) (NCCTG trial N027D) Is Associated with Increased Infectious Risks (2010) (71)
- Migratory behavior of lymphocytes isolated from multiple sclerosis patients: Effects of interferon β‐1b therapy (1999) (71)
- North Central Cancer Treatment Group Phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in patients with newly diagnosed glioblastoma multiforme. (2011) (70)
- Hypofractionated Stereotactic Radiation Therapy: An Effective Therapy for Recurrent High-Grade Gliomas (2011) (70)
- The neurocognitive effects of radiation in adult low-grade glioma patients. (2003) (67)
- MGMT Promoter Methylation Status Can Predict the Incidence and Outcome of Pseudoprogression After Concomitant Radiochemotherapy in Newly Diagnosed Glioblastoma Patients (2009) (64)
- IDH1 and IDH2 Mutations in Gliomas (2009) (62)
- PTEN Loss Does Not Predict for Response to RAD001 (Everolimus) in a Glioblastoma Orthotopic Xenograft Test Panel (2008) (59)
- Bevacizumab Safety in Patients with Central Nervous System Metastases (2010) (55)
- Recurrent Papillary Craniopharyngioma with BRAF V600E Mutation Treated with Dabrafenib: A Case Report (2018) (54)
- Prevalence and characteristics of central nervous system involvement by chronic lymphocytic leukemia (2016) (53)
- Revisiting Adjuvant Radiotherapy After Gross Total Resection of World Health Organization Grade II Meningioma. (2017) (50)
- Temozolomide in Elderly Patients With Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (2012) (50)
- Elevated levels of M(r) 92,000 type IV collagenase during tumor growth in vivo (1998) (50)
- Glioma invasionin vitro: regulation by matrix metalloprotease-2 and protein kinase C (1996) (46)
- Genetic and signaling pathway alterations in glioblastoma: relevance to novel targeted therapies. (2003) (45)
- Galectin-1, a gene preferentially expressed at the tumor margin, promotes glioblastoma cell invasion (2012) (44)
- Age‐dependent decrease of process formation by cultured oligodendrocytes is augmented by protein kinase C stimulation (1991) (43)
- Temozolomide Rechallenge in Recurrent Malignant Glioma by Using a Continuous Temozolomide Schedule: The “Rescue” Approach (2009) (41)
- Adult Low-grade Glioma: 19-year Experience at a Single Institution (2013) (40)
- Clinical significance and novel mechanism of action of kallikrein 6 in glioblastoma. (2013) (38)
- Congress of Neurological Surgeons Systematic Review and Evidence‐Based Guidelines on Emerging Therapies for the Treatment of Patients With Vestibular Schwannomas (2018) (38)
- Enhanced protein kinase C activity correlates with the growth rate of malignant gliomas in vitro. (1991) (33)
- Overall survival in patients with glioblastoma before and after bevacizumab approval (2018) (33)
- Elevated levels of Mr 92,000 type IV collagenase during tumor growth in vivo. (1998) (33)
- Phase II study of ZD1839 in patients with newly diagnosed grade 4 astrocytoma. (2004) (31)
- Cerebrovascular Events After Bevacizumab Treatment: An Early and Severe Complication (2011) (31)
- The impact of concurrent temozolomide with adjuvant radiation and IDH mutation status among patients with anaplastic astrocytoma (2014) (30)
- Altered actin cytoskeleton and inhibition of matrix metalloproteinase expression by vanadate and phenylarsine oxide, inhibitors of phosphotyrosine phosphatases: Modulation of migration and invasion of human malignant glioma cells (1999) (27)
- Phase II study of ZD1839 in patients with newly diagnosed grade 4 astrocytoma (2004) (25)
- Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs time to neurologic progression in non–small-cell lung cancer patients with brain metastases: results of a phase III trial (2009) (21)
- ATIM-14. ALLIANCE A071101: A PHASE II RANDOMIZED TRIAL COMPARING THE EFFICACY OF HEAT SHOCK PROTEIN PEPTIDE COMPLEX-96 (HSPPC-96) VACCINE GIVEN WITH BEVACIZUMAB VERSUS BEVACIZUMAB ALONE IN THE TREATMENT OF SURGICALLY RESECTABLE RECURRENT GLIOBLASTOMA (2017) (21)
- Long-term Anti-inflammatory and Antihistamine Medication Use and Adult Glioma Risk (2009) (19)
- Presentation, management, and outcome of elderly patients with newly-diagnosed anaplastic astrocytoma (2012) (18)
- Seizures in patients with primary brain tumors: what is their psychosocial impact? (2016) (16)
- Treatment of Glioma in the 21st Century: An Exciting Decade of Postsurgical Treatment Advances in the Molecular Era (2017) (16)
- Initial results of a phase II trial of 18F-DOPA PET-guided dose-escalated radiotherapy for glioblastoma. (2021) (15)
- Oxygen Is a Master Regulator of the Immunogenicity of Primary Human Glioma Cells (2012) (15)
- Gene Expression Profile Correlates with T-Cell Infiltration and Relative Survival in Glioblastoma Patients Vaccinated with Dendritic Cell Immunotherapy (2011) (13)
- Initial Results of a Phase II Trial of 18f-Dopa Pet-guided Dose-escalated Radiotherapy for Glioblastoma (2020) (12)
- Neurologic complications of cancer therapy (1999) (11)
- IDH-wild-type glioblastoma cell density and infiltration distribution influence on supramarginal resection and its impact on overall survival: a mathematical model. (2021) (10)
- Aberrant p 53 , mdm 2 , and Proliferation Differ in Glioblastomas from Long-Term Compared with Typical Survivors 1 (2002) (9)
- Phase I trial of erlotinib with radiation therapy (RT) in patients with glioblastoma multiforme (GBM) (2005) (9)
- Incidence, Characteristics, and Implications of Seizures in Patients With Glioblastoma (2017) (8)
- Primary Diffuse Leptomeningeal Gliomatosis (2009) (8)
- Phase II NCCTG trial of RT + irinotecan and adjuvant BCNU plus irinotecan for newly diagnosed GBM (2010) (7)
- Patient-reported outcomes, emoji, and activity measured on the Apple Watch in cancer patients. (2018) (7)
- NCCTG phase II trial of bevacizumab in combination with sorafenib in recurrent GBM. (2010) (6)
- Phase III Randomized Study of Postradiotherapy Chemotherapy with a-Difluoromethylornithine-Procarbazine , N-( 2-Chloroethyl )-N *-cyclohexyl-N-nitrosurea , Vincristine ( DFMO-PCV ) Versus PCV for Glioblastoma Multiforme 1 (2000) (6)
- Comparison of survival endpoints in glioblastoma patients receiving or not receiving enzyme-inducing anticonvulsants in NCCTG Trials. (2004) (5)
- Anaplastic Glioma: Treatment Approaches in the Era of Molecular Diagnostics (2018) (5)
- Bevacizumab Use in Refractory Adult Pilocytic Astrocytoma: A Single-Center Case Series (2019) (5)
- Managing Common Complex Symptomatic Epilepsies: Tumors and Trauma (2013) (5)
- NCCTG phase I trial of temsirolimus (CCI-779) and temozolomide (TMZ) in combination with radiation therapy (RT) in newly diagnosed glioblastoma multiforme (GBM) patients. (2009) (4)
- A “Vascular Normalization Index” as Potential Mechanistic Biomarker to Predict Survival after a Single Dose of Cediranib in Recurrent Glioblastoma Patients (2010) (4)
- TTF-1 positive posterior pituitary tumor: Limitations of current treatment and potential new hope in BRAF V600E mutation variants (2020) (4)
- Panobinostat in adults with H3 K27M-mutant diffuse midline glioma: a single-center experience (2022) (3)
- Modern reirradiation for recurrent gliomas can safely delay tumor progression. (2018) (3)
- Overall survival in patients with glioblastoma before and after bevacizumab approval. (2016) (3)
- A comprehensive study on spindle cell oncocytoma of the pituitary gland: series of 6 cases and meta-analysis of 85 cases. (2021) (3)
- Scale to Predict Survival After Surgery for Recurrent Glioblastoma Multiforme (2011) (2)
- Phase II Study of Bevacizumab Plus Temozolomide During and After Radiation Therapy for Patients With Newly Diagnosed Glioblastoma Multiforme (2012) (2)
- Predicting access to postoperative treatment after glioblastoma resection: an analysis of neighborhood-level disadvantage using the Area Deprivation Index (ADI) (2022) (2)
- Impact of adjuvant temozolomide and IDH mutation status among patients with anaplastic astrocytoma. (2013) (2)
- NCCTG N057K phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: A North Central Cancer Treatment Group trial. (2012) (2)
- ACTR-12. PRELIMINARY SAFETY AND EFFICACY OF A PHASE II TRIAL OF 18F-DOPA PET-GUIDED, DOSE-ESCALATED RADIOTHERAPY IN THE TREATMENT OF GLIOBLASTOMA (2018) (2)
- Central Nervous System Involvement By Chronic Lymphocytic Leukemia (2015) (2)
- Cross-species hybridization of microarrays for studying tumor transcriptome of brain metastasis (2012) (2)
- Neuro-oncology (2019) (2)
- Effect of combined therapy with temsirolimus (CCI-779), temozolomide (TMZ), and radiation (RT) in newly diagnosed glioblastoma multiforme (GBM) patients on immune suppression: Results from NCCTG N027D. (2010) (1)
- Medical and Neuro-Oncology (2010) (1)
- Galectin-1, a gene preferentially expressed at the tumor margin, promotes glioblastoma cell invasion (2012) (1)
- Title Galectin-1 , a gene preferentially expressed at the tumor margin , promotes glioblastoma cell invasion Permalink (2012) (1)
- Glutamate release by primary brain tumors induces epileptic activity (2012) (1)
- NCCTG Phase I Trial N057K of Everolimus (RAD001) and Temozolomide in Combination with Radiation Therapy in Newly Diagnosed Glioblastoma Multiforme Patients 1 (2011) (1)
- Inhibitory Effect of Pirfenidone on Glioblastoma Cell Lines: Implications for Treatment of Neurofibromatosis (2007) (1)
- Factors Contributing to Survival in Patients With Anaplastic Astrocytoma: A Retrospective Study of Patients Treated at a Single Institution (2013) (1)
- Temozolomide desensitization followed by metronomic dosing in patients with hypersensitivity (2020) (1)
- Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised, controlled trial (2012) (1)
- Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma (2011) (0)
- RTHP-08. LONG-TERM FOLLOW UP OF HIGH-RISK LOW-GRADE GLIOMA PATIENTS TREATED WITH RADIOTHERAPY (RT) OR RT AND ADJUVANT TEMOZOLAMIDE OR PROCARBAZINE, CCNU, AND VINCRISTINE (PCV) CHEMOTHERAPY AT A SINGLE INSTITUTION (2016) (0)
- N997D: Pilot trial of CPT11 during RT followed by CPT11 and BCNU in newly diagnosed glioblastoma (GBM) patients: A North Central Cancer Group (NCCTG) study (2005) (0)
- Kallikrein 6, a degradative serine proteinase, is expressed by glioblastoma cells in vivo (2004) (0)
- Targeted therapy for glioblastomas: pirfenidone, an anti-fibrotic agent that inhibits epidermal growth factor receptor phosphorylation (2002) (0)
- Spinal Cord Tumors (2015) (0)
- PATH-47. TTF MAY APPLY SELECTIVE PRESSURE TO GLIOBLASTOMA CLONES WITH ANEUPLOIDY: A CASE REPORT (2019) (0)
- Five Decades of Adult Low-grade Gliomas: Patterns of Care Over Time (2012) (0)
- RARE-37. TREATMENT OF H3K27M MUTANT GLIOMAS WITH PANOBINOSTAT (2019) (0)
- Initial results of a phase II trial of 18F-DOPA PET-guided re-irradiation for recurrent high-grade glioma (2022) (0)
- NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide (2010) (0)
- Genome-Wide Analyses Identify Recurrent Amplifications of Receptor Tyrosine Kinases and Cell-Cycle Regulatory Genes in Diffuse Intrinsic Pontine Glioma (2012) (0)
- Mosaic Amplification of Multiple Receptor Tyrosine Kinase Genes in Glioblastoma (2012) (0)
- Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system (2011) (0)
- RADT-15. 18F-DOPA PET/CT SURVEILLANCE FOR GLIOBLASTOMA: A RADIOMIC MODEL FROM A PROSPECTIVE PHASE II CLINICAL TRIAL PREDICTING SURVIVAL IN IDH-WILDTYPE, MGMT-UNMETHYLATED PATIENTS (2022) (0)
- Impact of Intraoperative Stimulation Brain Mapping on Glioma Surgery Outcome: A Meta-Analysis (2012) (0)
- INNV-15. MANAGEMENT AND LONG-TERM OUTCOMES OF ADULTS WITH MEDULLOBLASTOMA (2022) (0)
- P01.001 Bevacizumab use in adult pilocytic astrocytoma, a single center experience (2018) (0)
- RARE-04. TARGETED TREATMENT OF PAPILLARY CRANIOPHARYNGIOMAS HARBORING BRAFV600E MUTATIONS (2019) (0)
- Abstract C56: NCCTG phase I trial of everolimus (RAD001) and temozolomide (TMZ) in combination with radiation therapy (RT) in newly diagnosed glioblastoma multiforme (GBM) patients (2009) (0)
- Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice (2010) (0)
- Cancer esearch cer Therapy : Clinical bination of Temsirolimus ( CCI-779 ) with Chemoradiation ewly Diagnosed Glioblastoma Multiforme ( GBM ) CTG trial N 027 D ) Is Associated with R eased Infectious Risks (2010) (0)
- Biological Response Modifiers in the Treatment of Malignant Brain Tumours (1998) (0)
- Modern Re-irradiation Versus Post-Bevacizumab Salvage Chemotherapy in Treating Recurrent High-Grade Gliomas (2018) (0)
- Cerebro-Sino-Orbital Mucormycosis: Case Report of Novel Biopsy Technique and Review of Literature (2014) (0)
- 18F-DOPA-PET-Guided Re-Irradiation for Recurrent High-Grade Glioma: Initial Results of a Phase II Trial. (2021) (0)
- Mutations in CIC and FUBP1 Contribute to Human Oligodendroglioma (2012) (0)
- CTNI-28. VOLUMETRIC AND DOSIMETRIC PATTERNS OF FAILURE ANALYSIS OF A PHASE II CLINICAL TRIAL OF 18F-DOPA-PET DIRECTED DOSE ESCALATED RADIOTHERAPY FOR GLIOBLASTOMA (2021) (0)
- Descriptive Statistics for Patients with Glioblastoma Associated with Germline Mismatch Repair Gene Mutation (2022) (0)
- Management and Long-Term Outcomes of Patients With Recurrent Stroke-Like Episodes After Cranial Radiotherapy. (2021) (0)
- NFKBIA Deletion in Glioblastomas (2012) (0)
- Cancer Therapy : Clinical Phase II StudyofBevacizumab inCombinationwithSorafenib in Recurrent Glioblastoma ( N 0776 ) : A North Central Cancer Treatment Group Trial (2013) (0)
- Intrinsic Gene Expression Profiles of Gliomas Are a Better Predictor of Survival than Histology (2010) (0)
- Early Post Radiation Neuropathy: Complex Pathogenesis Including Microvasculitis and Tumor Spread (P14-8.001) (2023) (0)
- A phase I clinical trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinoma. (2010) (0)
- PTENLoss Does Not Predict for Response to RAD 001 ( Everolimus ) in a Glioblastoma Orthotopic XenograftTest Panel (2008) (0)
- Genomic markers of recurrence risk in atypical meningioma following gross total resection (2022) (0)
- Single-Institution Experience of Low-Grade Glioma Patient Outcomes Eligible for RTOG 9802 (2016) (0)
- Diagnostic Role of Lumbar Puncture (LP) for the diagnosis of Central Nervous System (CNS) Involvement by Chronic Lymphocytic Leukemia(CLL)/Richter Syndrome (RS) (2015) (0)
- Temozolomide retreatment after desensitization in glioma patients with temozolomide hypersensitivity (2017) (0)
- Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial (2012) (0)
This paper list is powered by the following services:
